Vindesine in relapsed childhood ALL. A pilot study by the United Kingdom Children's Cancer Study Group
European Paediatric Haematology and Oncology · 1984
DOI: 10.3109/08880018409141706 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Paediatric Haematology and Oncology, 1984. Verfasst von Js Lilleyman und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Twenty-three children with first on-treatment marrow relapse of lymphoblastic leukaemia (ALL) were randomly assigned to treatment with vincristine (16 patients) or vindesine (7 patients) in an otherwise identical regimen including daunorubicin, prednisolone, asparaginase, VM26 and cytosine. There was no suggestion of any difference between the two groups in terms of frequency of secbnd remission achievement or duration, nor was there in terms of toxicity. Despite small numbers, these findings suggest that vindesine does not offer any obvious therapeutic advantage over vincristine in relapsed ALL, but is well tolerated.
Zitieren
APA
Lilleyman, J., & Campbell, R. (1984). Vindesine in relapsed childhood ALL. A pilot study by the United Kingdom Children's Cancer Study Group. European Paediatric Haematology and Oncology. https://doi.org/10.3109/08880018409141706
Vancouver
Lilleyman J, Campbell R. Vindesine in relapsed childhood ALL. A pilot study by the United Kingdom Children's Cancer Study Group. European Paediatric Haematology and Oncology. 1984. doi:10.3109/08880018409141706
BibTeX
@article{Lilleyman1984,
author = {Lilleyman, Js and Campbell, Rha},
title = {Vindesine in relapsed childhood ALL. A pilot study by the United Kingdom Children's Cancer Study Group},
journal = {European Paediatric Haematology and Oncology},
year = {1984},
doi = {10.3109/08880018409141706}
}
EUVIMED